The Lupus Foundation of America supports efforts to lower patient out of pocket costs in Medicare Part B, which provides people with lupus access to critical medications including the only drug approved to treat the disease. However, we are deeply concerned that the Administration’s Most Favored Nation rule may limit patient access to current and future therapies. Moreover, we are troubled that the Administration is rushing to implement such a significant and complex change without allowing for public comment and input from the patient communities most impacted by this rule. We strongly oppose this rule and believe that those living with lupus in the United States should have access to the full range of treatment options and not have those options limited by the decisions made in foreign countries.